The Efficacy of Retinoic Acid in Patients with Radioiodine-Refractory Thyroid Cancer: A Meta-analysis

被引：0
|
作者：
Shin, Seunghyeon [1 ]
Pak, Kyoungjune [1 ]
Kim, Seong-Jang [1 ]
Kim, In Joo [1 ]
机构：
[1] Pusan Natl Univ Hosp, Busan, South Korea
来源：
JOURNAL OF NUCLEAR MEDICINE | 2016年 / 57卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
1702
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib
    Platini, F.
    Cavalieri, S.
    Alfieri, S.
    Bergamini, C.
    Resteghini, C.
    Bottiglieri, A.
    Colombo, E.
    Mazzeo, L.
    Licitra, L.
    Paolini, B.
    Seregni, E.
    Locati, L. D.
    ENDOCRINE, 2021, 73 (03) : 641 - 647
  • [42] Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib
    F. Platini
    S. Cavalieri
    S. Alfieri
    C. Bergamini
    C. Resteghini
    A. Bottiglieri
    E. Colombo
    L. Mazzeo
    L. Licitra
    B. Paolini
    E. Seregni
    L. D. Locati
    Endocrine, 2021, 73 : 641 - 647
  • [43] Exploratory Analysis of Prognostic and Predictive Factors of Lenvatinib for Radioiodine-Refractory Differentiated Thyroid Cancer
    Suzuki, C.
    Kiyota, N.
    Imamura, Y.
    Goto, H.
    Suto, H.
    Chayahara, N.
    Toyoda, M.
    Ito, Y.
    Miya, A.
    Miyauchi, A.
    Otsuki, N.
    Nibu, K. I.
    Minami, H.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 100 (05): : 1386 - 1387
  • [44] Novel Drug Treatments of Progressive Radioiodine-Refractory Differentiated Thyroid Cancer
    Weitzman, Steven P.
    Sherman, Steven, I
    ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 2019, 48 (01) : 253 - +
  • [45] Novel therapeutic options for radioiodine-refractory thyroid cancer: redifferentiation and beyond
    Bulotta, Stefania
    Celano, Marilena
    Costante, Giuseppe
    Russo, Diego
    CURRENT OPINION IN ONCOLOGY, 2020, 32 (01) : 13 - 19
  • [46] Exploratory Analysis to Predict Optimal Tumor Burden for Starting Lenvatinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer
    Suzuki, Chiaki
    Kiyota, Naomi
    Imamura, Yoshinori
    Goto, Hideaki
    Suto, Hirotaka
    Chayahara, Naoko
    Toyoda, Masanori
    Ito, Yasuhiro
    Miya, Akihiro
    Miyauchi, Akira
    Teshima, Masanori
    Otsuki, Naoki
    Nibu, Ken-ichi
    Minami, Hironobu
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [47] A proposed clinical scoring system for initiation of lenvatinib treatment in radioiodine-refractory thyroid cancer patients
    Fukuda, Naoki
    Toda, Kazuhisa
    Udagawa, Shohei
    Ohmoto, Akihiro
    Oki, Ryosuke
    Suto, Hirotaka
    Wang, Xiaofei
    Hayashi, Naomi
    Urasaki, Tetsuya
    Sato, Yasuyoshi
    Nakano, Kenji
    Ono, Makiko
    Tomomatsu, Junichi
    Mitani, Hiroki
    Takahashi, Shunji
    ENDOCRINE, 2022, 76 (01) : 70 - 77
  • [48] Response to lenvatinib treatment in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC)
    Gianoukakis, Andrew G.
    Mathias, Elton
    Dutcus, Corina E.
    Young, Louise
    Kalantari, Parmida
    Yoon, Steve
    CLINICAL ENDOCRINOLOGY, 2017, 86 : 68 - 68
  • [49] Efficacy and Limitations of Lenvatinib Therapy for Radioiodine-Refractory Differentiated Thyroid Cancer: Real-World Experiences
    Masaki, Chie
    Sugino, Kiminori
    Saito, Naoko
    Akaishi, Junko
    Hames, Kiyomi Y.
    Tomoda, Chisato
    Suzuki, Akifumi
    Matsuzu, Kenichi
    Uruno, Takashi
    Ohkuwa, Keiko
    Kitagawa, Wataru
    Nagahama, Mitsuji
    Ito, Koichi
    THYROID, 2020, 30 (02) : 214 - 221
  • [50] Feasibility of Apatinib in Radioiodine-Refractory Differentiated Thyroid Carcinoma
    Du, Wei
    Shi, Xiangyu
    Fang, Qigen
    Zhang, Xu
    Liu, Shanting
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
12345